The Narrative Machine: What AI Really Adds to Personal Health Data
For years, the Quantified Self movement had a stubborn problem: our devices became increasingly good at generating data but remained remarkably poor at telling us... Read More
Biotech Leaders Get It
About David Shaywitz
David Shaywitz, MD PhD is a contributing writer for Timmerman Report.
Focus: the transformational opportunities and implementation challenges presented by emerging technologies in healthcare, biomedical discovery, and biopharmaceutical development, from NGS and cell therapies to digital biomarkers and the meaningful application of AI. Co-author (with Lisa Suennen): Tech Tonics: Can Passionate Entrepreneurs Heal Healthcare With Technology? (Hyperink Press, 2014).
Background: Drawing on two decades of biopharma experience, Dr. Shaywitz applies deep R&D expertise to guide and invest in the strategic adoption of emerging technologies to accelerate the discovery, development and delivery of impactful new therapies for patients.
Dr. Shaywitz’s career has centered on advancing pharmaceutical research by appreciating the transformative potential of nascent technologies while also recognizing the unique challenges of incorporating these technologies into complex biopharma environments. He has particular expertise in guiding promising technology and technology innovators through the complex scientific, cultural, and organizational landscape of biopharma.In addition to his writing for TR, Dr. Shaywitz is also a frequent speaker and writer on topics at the intersection of medicine, science, and innovation, and contributes book reviews regularly to the Wall Street Journal.
Dr. Shaywitz serves as a lecturer in the Department of Biomedical Informatics at Harvard Medical School, is an advisor to the MS/MBA Biotechnology Life Science Program at Harvard GSAS/HBS, and is an Adjunct Scholar at the American Enterprise Institute.
Latest Contributions
The Other Side of Bayes: Rethinking False Positives in Health Screening
Imagine screening 10,000 apparently healthy people for a disease that affects one person in a thousand. Let’s further assume the test is fairly good: 99%... Read More
AI in Drug R&D: At Last, the End of the Beginning
With the emergence of AI as an increasingly dominant force in industry (and society), much of the early discussion around AI in biopharma has tended... Read More
Useful Fictions or Distorting Frames? How Models Shape Drug R&D
We rely on models — deliberate simplifications — to navigate, make sense of, and engage productively with an ever-more complicated world. Patients understand their illnesses... Read More
Wellness Tech: Don’t Use as Directed
The Great Technology Plan for Wellness, to simplify only slightly, envisions a path to health that runs through data: collect more (through wearables and blood... Read More
Summer Content Recommendations
Back by popular demand – my highly curated list of summer content recommendations for TR readers. Books Inside the Box – David Epstein By now,... Read More
Can AI-Powered Consumer Health Break Medicine’s Destructive Spiral?
This week’s Duke-Margolis Health Policy Conference (video here) left me feeling there’s a remarkable opportunity to leverage technology to dramatically improve healthcare — and there’s... Read More
AI in Practice
AI is here – everywhere it seems. How are we doing on translating this extraordinary promise into palpable value? Organizations As utopian AI “Accelerationists” have... Read More